Plant Protein Hydrolysates and Bioactive Peptides

Lunasin and Plant-Derived Peptides

200+ peptides

Over 200 bioactive peptides have been identified from legume protein hydrolysates alone, with ACE-inhibitory, antioxidant, and antidiabetic activities documented in vitro and in animal models.

Gharibzahedi et al., Critical Reviews in Food Science and Nutrition, 2024

Gharibzahedi et al., Critical Reviews in Food Science and Nutrition, 2024

View as image

Plant proteins contain bioactive peptides locked inside their amino acid sequences. These peptides are inactive while embedded in the parent protein. Enzymatic hydrolysis, the controlled use of proteases to cleave peptide bonds, releases these encrypted fragments and activates their biological properties. The resulting hydrolysates contain mixtures of peptides with documented effects on blood pressure, oxidative stress, blood sugar regulation, and satiety signaling.

Lunasin, the 43-amino acid soy-derived peptide, is the best-known example of a plant bioactive peptide. But the field extends far beyond a single peptide. Researchers have identified bioactive peptides from pea, wheat, rice, quinoa, lupin, amaranth, walnut, and corn proteins. Gharibzahedi et al. (2024) reviewed the landscape and documented over 200 individual bioactive peptides released from legume protein hydrolysates alone.^[1]

How enzymatic hydrolysis works

Proteins are long chains of amino acids linked by peptide bonds. Enzymatic hydrolysis uses proteases, enzymes that specifically cleave these bonds, to break proteins into smaller fragments. The process operates under mild conditions (typically 37-60 degrees C, near-neutral pH) compared to acid or alkaline hydrolysis, preserving the biological activity of the released peptides.

The choice of enzyme determines which peptide bonds are cut and, therefore, which peptide sequences are released. Common proteases used in plant protein hydrolysis include:

Alcalase. A broad-specificity serine endoprotease from Bacillus licheniformis. Produces diverse peptide mixtures and is widely used in industrial food processing. Sharma et al. (2023) used alcalase as part of a two-step hydrolysis of corn distillers solubles protein, generating hydrolysates with both ACE and DPP-IV inhibitory activities.^[2]

Pepsin. The primary gastric protease. Elbira et al. (2025) demonstrated that pepsin digestion of pre-hydrolyzed pea protein released bioactive peptides with antidiabetic and antihypertensive functions. Pre-hydrolysis using alcalase or trypsin before pepsin treatment increased peptide yield and bioactivity, suggesting that sequential enzyme treatment opens up protein structures that single-enzyme approaches miss.^[3]

Trypsin and chymotrypsin. Pancreatic serine proteases that mimic the enzymes encountered during gastrointestinal digestion. Trypsin cleaves specifically after lysine and arginine residues. These enzymes are used to simulate what happens to plant proteins during normal digestion.

The degree of hydrolysis (DH), the percentage of peptide bonds cleaved, directly affects the bioactive profile. Low DH (<10%) tends to produce larger peptide fragments. Higher DH produces smaller peptides but can also destroy bioactive sequences through over-digestion. Optimal DH for bioactive peptide release varies by protein source and target activity.

ACE-inhibitory peptides: the blood pressure connection

The most extensively studied bioactivity of plant protein hydrolysates is inhibition of angiotensin-converting enzyme (ACE). ACE converts angiotensin I to angiotensin II, a potent vasoconstrictor that raises blood pressure. Synthetic ACE inhibitors (captopril, enalapril) are among the most prescribed antihypertensive drugs. Plant-derived ACE-inhibitory peptides work through the same mechanism.

Rice

Li et al. (2007) produced rice protein hydrolysates using alcalase and demonstrated ACE-inhibitory activity in vitro. When administered orally to spontaneously hypertensive rats, the hydrolysate reduced systolic blood pressure by 25.6 mmHg. The active peptide fraction was identified and its ACE-binding confirmed.^[4]

Wheat

Zou et al. (2020) produced wheat bran protein hydrolysates with both antihypertensive and antioxidant activities. Using enzymatic hydrolysis conditions optimized for ACE inhibition, the researchers identified peptide fractions with IC50 values in the micromolar range. The dual functionality (blood pressure and oxidative stress) is common in plant hydrolysates because small hydrophobic peptides tend to exhibit both activities.^[5]

Lupin

Fadimu et al. (2023) used non-thermal pretreatment followed by enzymatic hydrolysis to release novel antihypertensive peptides from lupin protein. In-silico identification and molecular docking studies confirmed that the released peptides bind ACE at the same active site as pharmaceutical inhibitors. The non-thermal pretreatment (ultrasonication) unfolded the protein structure, exposing previously buried peptide bonds to enzymatic cleavage.^[6]

Quinoa

De Carvalho Oliveira et al. (2024) combined high hydrostatic pressure with enzymatic hydrolysis of quinoa proteins. The pressure treatment enhanced catalytic efficiency and produced hydrolysates with antioxidant and ACE-inhibitory activities superior to those from conventional hydrolysis at atmospheric pressure. The pressure partially unfolds protein structures, increasing the number of cleavage sites accessible to the enzyme.^[7]

Amaranth

Cruz-Casas et al. (2025) took a different approach: fermentation with Enterococcus faecium-LR9, a lactic acid bacterium with proteolytic activity, to hydrolyze amaranth seed proteins. The resulting hydrolysate contained ACE-inhibitory peptides identified by mass spectrometry and confirmed by molecular docking to bind the ACE catalytic site. This fermentation-based approach is relevant to traditional food production, where fermented grain products may contain bioactive peptides as a natural consequence of microbial proteolysis.^[8]

Walnut

Xie et al. (2024) identified a novel ACE-inhibitory peptide (YGNPVGGVGH) from walnut protein hydrolysate using in silico screening followed by in vivo validation. The peptide reduced blood pressure in angiotensin II-induced hypertensive rats. Molecular dynamics simulations showed stable binding to the ACE active site through hydrogen bonding and hydrophobic interactions.^[9]

Corn

Sharma et al. (2023) valorized corn distillers solubles, a low-value byproduct of ethanol production, as a source of plant-based protein hydrolysates. Two-step proteolytic hydrolysis (alcalase followed by trypsin or pepsin) produced hydrolysates with ACE and DPP-IV inhibitory activities. This demonstrates that bioactive peptide production can utilize agricultural waste streams, not just premium food-grade proteins.^[2]

Beyond blood pressure: other bioactivities

Antidiabetic effects

DPP-IV (dipeptidyl peptidase-4) degrades the incretin hormones GLP-1 and GIP that regulate blood sugar. Pharmaceutical DPP-IV inhibitors (sitagliptin, saxagliptin) are used in type 2 diabetes management. Plant protein hydrolysates contain peptides that inhibit DPP-IV in vitro.

Elbira et al. (2025) showed that pre-hydrolyzed pea protein digested with pepsin released peptides with DPP-IV inhibitory activity. The pre-hydrolysis step was critical: it disrupted the compact globular structure of pea proteins, making more cleavage sites accessible and increasing the yield of bioactive peptides.^[3] Whether the DPP-IV inhibition measured in these in vitro assays translates to clinically meaningful blood sugar reduction in humans remains unestablished.

Antioxidant activity

Many plant protein-derived peptides scavenge free radicals and chelate pro-oxidant metal ions. The antioxidant activity often correlates with the presence of hydrophobic amino acids (leucine, valine, alanine) and aromatic residues (tyrosine, tryptophan, phenylalanine) in the peptide sequence.

Zou et al. (2020) found that wheat bran hydrolysates exhibited DPPH radical scavenging, ABTS radical scavenging, and ferric reducing antioxidant power, with activity increasing as the degree of hydrolysis increased up to an optimal point.^[5] The practical significance of in vitro antioxidant activity for human health is debated, as peptide bioavailability after oral consumption may not achieve the concentrations tested in cell-free assays.

Satiety and appetite regulation

Foltz et al. (2008) demonstrated that protein hydrolysates stimulate cholecystokinin (CCK) release from enteroendocrine cells. CCK is a satiety hormone that signals fullness to the brain. The hydrolysates acted as partial agonists at the CCK1 receptor, suggesting a direct receptor-mediated mechanism rather than simply a caloric effect. Casein hydrolysates were tested, but the principle applies to plant protein hydrolysates containing similar peptide sequences.^[10]

This connects to a broader trend: protein-rich meals produce more satiety than carbohydrate or fat-rich meals, and part of this effect may be mediated by bioactive peptides released during digestion rather than protein per se.

Lunasin: the paradigm plant bioactive peptide

Lunasin, first isolated from soybean, represents the most extensively characterized single plant-derived bioactive peptide.

Lule et al. (2015) reviewed lunasin's health benefits, documenting anticancer, anti-inflammatory, antioxidant, and cholesterol-lowering properties. Unlike most plant bioactive peptides that are released by hydrolysis, lunasin exists as a discrete 43-amino acid peptide within soy protein and can be extracted intact. It resists gastrointestinal digestion, surviving transit to reach the intestinal epithelium in bioactive form.^[11]

Jeong et al. (2007) demonstrated that lunasin inhibits core histone acetylation, a mechanism relevant to cancer prevention. Histone acetylation is an epigenetic modification that regulates gene expression; aberrant acetylation is associated with cancer cell proliferation. Lunasin binds deacetylated histones and prevents their acetylation by histone acetyltransferases.^[12]

Lunasin is exceptional among plant bioactive peptides in having a defined molecular target and mechanism. Most peptides identified from hydrolysates are characterized by in vitro assay results (ACE inhibition, radical scavenging) without detailed mechanistic understanding.

Processing methods that affect peptide release

The bioactive peptide profile of a plant protein hydrolysate depends on multiple processing variables.

Protein pretreatment. Fadimu et al. (2023) showed that ultrasonication before enzymatic hydrolysis of lupin protein increased ACE-inhibitory peptide yield by unfolding protein tertiary structure.^[6] High hydrostatic pressure pretreatment produced similar benefits for quinoa protein.^[7] Thermal pretreatment (cooking, autoclaving) also denatures proteins but can simultaneously destroy heat-sensitive bioactive peptides.

Enzyme selection and combination. Sequential hydrolysis with multiple enzymes produces different peptide profiles than single-enzyme approaches. Elbira et al. (2025) demonstrated that pre-hydrolysis with alcalase or trypsin followed by pepsin digestion of pea protein released peptides that neither enzyme alone could produce.^[3]

Fermentation. Microbial fermentation offers an alternative to purified enzyme treatment. Cruz-Casas et al. (2025) used lactic acid bacteria with intrinsic proteolytic activity to hydrolyze amaranth protein.^[8] This approach is relevant to traditional fermented foods (tempeh, miso, fermented grain beverages) that may contain bioactive peptides as a natural consequence of the fermentation process.

Legume-derived bioactive peptides from beans, lentils, and chickpeas are covered in more detail in the dedicated article, and cereal grain peptides from wheat, rice, and oats have their own evidence base.

Limitations and the bioavailability problem

The largest gap in plant protein hydrolysate research is the distance between in vitro bioactivity and in vivo efficacy.

Bioavailability. Peptides identified as ACE-inhibitory or antioxidant in cell-free assays must survive gastrointestinal digestion, absorb across the intestinal epithelium, and reach target tissues at effective concentrations. Many di- and tripeptides are absorbed through intestinal peptide transporters (PepT1), but larger peptides face absorption barriers. The rice protein hydrolysate study by Li et al. (2007) is valuable precisely because it demonstrated in vivo blood pressure reduction after oral administration, confirming that at least some peptides survived digestion and reached their target.^[4]

Dose uncertainty. IC50 values from in vitro ACE or DPP-IV assays do not directly translate to dietary intake recommendations. The amount of a specific bioactive peptide in a food product depends on the protein content, the degree of hydrolysis during processing or digestion, and the stability of the peptide through the gastrointestinal tract.

Potency vs. pharmaceuticals. Plant-derived ACE-inhibitory peptides are orders of magnitude less potent than pharmaceutical ACE inhibitors like captopril. Their potential value lies in chronic dietary exposure rather than acute pharmacological effect, but long-term clinical trials demonstrating sustained blood pressure benefits from peptide-enriched foods are limited.

Bitterness. Hydrolysis of plant proteins often produces bitter peptides due to the exposure of hydrophobic amino acid residues. This limits consumer acceptance of hydrolysate-enriched food products and is a significant barrier to commercial application.

Cross-cluster connections exist with collagen peptides for joint health, which face similar bioavailability questions, and lactotripeptides for blood pressure, which represent the dairy-derived parallel to plant ACE-inhibitory peptides.

The Bottom Line

Plant protein hydrolysates contain encrypted bioactive peptides released through enzymatic hydrolysis or fermentation. ACE-inhibitory peptides from rice, wheat, lupin, quinoa, amaranth, walnut, and corn proteins have demonstrated blood pressure reduction in animal models, while DPP-IV inhibitory peptides show antidiabetic potential in vitro. The gap between in vitro bioactivity and clinical efficacy remains the field's central challenge, with bioavailability, dose-response relationships, and potency compared to pharmaceuticals all unresolved. Processing variables including enzyme selection, pretreatment, and fermentation conditions determine which peptides are released and at what concentrations.

Frequently Asked Questions

What are plant protein hydrolysates?

Plant protein hydrolysates are mixtures of peptides and amino acids produced by breaking down plant proteins using enzymes (proteases), acid, or fermentation. Enzymatic hydrolysis is preferred because it operates under mild conditions that preserve bioactive peptide structures. Common sources include soy, pea, wheat, rice, quinoa, lupin, amaranth, and corn proteins. The resulting peptide mixtures contain fragments with documented biological activities including blood pressure reduction, antioxidant effects, and blood sugar regulation.

How do plant peptides lower blood pressure?

Plant-derived peptides can inhibit angiotensin-converting enzyme (ACE), the same target as pharmaceutical blood pressure drugs like captopril. ACE converts angiotensin I to angiotensin II, which constricts blood vessels and raises blood pressure. Li et al. (2007) showed that rice protein hydrolysate reduced systolic blood pressure by 25.6 mmHg in hypertensive rats through ACE inhibition. Similar peptides have been identified from wheat, lupin, quinoa, amaranth, walnut, and corn protein hydrolysates, though human clinical data is limited.

Are bioactive peptides from plants as effective as drugs?

Plant-derived bioactive peptides are substantially less potent than pharmaceutical ACE inhibitors or DPP-IV inhibitors. Their IC50 values (the concentration needed to inhibit 50% of enzyme activity) are typically orders of magnitude higher than drugs like captopril or sitagliptin. The proposed benefit comes from chronic dietary exposure rather than acute pharmacological dosing. Long-term clinical trials demonstrating sustained health benefits from peptide-enriched plant foods in humans remain limited.

What is enzymatic hydrolysis of plant protein?

Enzymatic hydrolysis uses proteases (protein-cutting enzymes) to break peptide bonds in plant proteins under controlled conditions, typically at 37-60 degrees C and near-neutral pH. Common enzymes include alcalase, pepsin, and trypsin. The degree of hydrolysis determines the peptide size distribution: too little hydrolysis produces large inactive fragments, while too much can destroy bioactive sequences. Sequential treatment with multiple enzymes, as Elbira et al. (2025) showed with pea protein, can release peptides that no single enzyme produces alone.

Which plant proteins have the most bioactive peptides?

Legumes (pea, soy, lupin, lentil, chickpea) have been most extensively studied, with Gharibzahedi et al. (2024) documenting over 200 bioactive peptides from legume hydrolysates alone. Soy is the most-researched source, partly due to lunasin, a 43-amino acid peptide with anticancer properties. Rice, wheat, quinoa, and amaranth grain proteins also yield ACE-inhibitory and antioxidant peptides. Walnut and other nut proteins are emerging sources. The bioactive profile depends on the specific enzyme and processing conditions used, not just the protein source.

Can you get bioactive peptides from eating plant foods?

Gastrointestinal digestion naturally hydrolyzes dietary proteins, releasing some bioactive peptides. Foltz et al. (2008) showed that protein hydrolysates stimulate CCK release from gut cells, promoting satiety. However, the specific peptides released during digestion depend on individual enzyme activity, gut transit time, and pH conditions, making the bioactive peptide yield variable between individuals. Fermented plant foods (tempeh, miso) may contain higher levels of pre-formed bioactive peptides due to microbial proteolysis during fermentation.